Melatonin Therapy for Elderly Patients with Sleep Disturbances

Introduction to Melatonin Therapy

The American Academy of Sleep Medicine recommends starting with a low dose of 1-2 mg immediate-release melatonin for elderly patients to mimic normal physiological circadian rhythm while avoiding prolonged blood levels 1
For sleep onset insomnia specifically in elderly patients (65-80 years), 2 mg of prolonged-release melatonin has shown significant reduction in sleep latency compared to placebo 1, 2

The American Academy of Sleep Medicine found that prolonged-release melatonin at 2 mg showed significant reduction in sleep latency specifically in elderly patients (65-80 years) 2
Studies evaluating melatonin use in Irregular Sleep-Wake Rhythm Disorder (ISWRD) in elderly with dementia have yielded inconsistent results, with the American Academy of Sleep Medicine suggesting against its use in this specific population 3

Melatonin has a favorable safety profile in elderly patients with minimal adverse effects reported 1
No clinically significant differences in adverse events between melatonin and placebo have been observed across various dosages and durations 1, 2
Unlike benzodiazepines, melatonin is not listed on the American Geriatrics Society Beers Criteria list of potentially inappropriate medications in older adults 1
Caution is advised when prescribing to patients taking warfarin and to patients with epilepsy due to potential interactions 2

Immediate-release formulations may be more effective than slow-release formulations for sleep onset issues 2
Lower doses of melatonin may be more effective than higher doses in some cases due to potential receptor desensitization with higher doses 2
Morning grogginess and "hangover" effects are more commonly reported with higher doses 2
Choose reputable formulations when possible for more reliable dosing 2
Begin with 1-2 mg immediate-release melatonin taken 30-60 minutes before bedtime 1
Evaluate effectiveness after 3 weeks of consistent use 1, 2

The evidence for melatonin use in primary insomnia is considered low quality by some guidelines 4, 2
Many studies on melatonin are of short duration, limiting conclusions about long-term safety 2